MedTrace Logo

Edaravone and Argatroban Stroke Therapy Study for Acute Ischemic Stroke

NCT00153946 · Status: COMPLETED · Phase: PHASE4 · Type: INTERVENTIONAL · Enrollment: 814

Last updated 2008-05-14

No results posted yet for this study

Summary

Edaravone, a free radical scavenger, is a novel neuroprotective agent, and argatroban is a selective thrombin inhibitor. Both the drugs were approved by the Japanese Government, and have frequently been used for the treatment of acute brain infarction in Japan. The effect of combination therapy of these drugs, however, has not yet been elucidated. This study will test the safety and efficacy of the combination therapy with these agents in patients with acute non-cardioembolic and non-lacunar ischemic stroke.

Conditions

Interventions

DRUG

Edaravone

30mg/20mL vial, twice per day, not longer than two weeks

Sponsors & Collaborators

  • Japan Cardiovascular Research Foundation

    collaborator OTHER

  • Combination Therapy for Acute Ischemic Stroke Study Group

    lead OTHER

Principal Investigators

  • Takenori Yamaguchi, MD, PhD · National Cerebral and Cardiovascular Center, Japan

  • Takenori Yamaguchi, MD, PhD · National Cerebral and Cardiovascular Center, Japan

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
20 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2004-08-31
Primary Completion
2008-03-31
Completion
2008-05-31

Countries

  • Japan

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00153946 on ClinicalTrials.gov